Marc Hilhorst

Dr. Marc Hilhorst

Amsterdam University Medical Center (UMC), Department of Internal Medicine, Division of Nephrology, 1105 AZ Amsterdam, The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 February 2016 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
Tsuyoshi ShiraiTsuyoshi Shirai
Tsuyoshi Shirai
RNRafal R. Nazarewicz
Rafal R. Nazarewicz
BWBarbara B. Wallis
Barbara B. Wallis
RYRolando E. Yanes
Rolando E. Yanes
Ryu WatanabeRyu Watanabe
Ryu Watanabe
Cornelia WeyandCornelia Weyand
Cornelia Weyand
Abnormal glucose metabolism and enhanced oxidative stress accelerate cardiovascular disease, a chronic inflammatory condition causing high morbidity and mortality. Here, we report that in monocytes and macrophages of patients with atherosclerotic coronary artery disease (CAD), overutilization of glucose promotes excessive and prolonged production of the cytokines IL-6 and IL-1β, driving systemic and tissue inflammation. In patient-derived monocytes and macrophages, increased glucose uptake and glycolytic flux fuel the generation of mitochondrial reactive oxygen species, which in turn promote dimerization of the glycolytic enzyme pyruvate kinase M2 (PKM2) and enable its nuclear translocation. Nuclear PKM2 functions as a protein kinase that phosphorylates the transcription factor STAT3, thus boosting IL-6 and IL-1β production. Reducing glycolysis, scavenging superoxide and enforcing PKM2 tetramerization correct the proinflammatory phenotype of CAD macrophages. In essence, PKM2 serves a previously unidentified role as a molecular integrator of metabolic dysfunction, oxidative stress and tissue inflammation and represents a novel therapeutic target in cardiovascular disease.

1 October 2015 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
Marc HilhorstMarc Hilhorst
Marc Hilhorst
PPPieter van Paassen
Pieter van Paassen
JTJan Willem Cohen Tervaert
Jan Willem Cohen Tervaert
FRFor The Limburg Renal Registry
For The Limburg Renal Registry
In patients with GN or vasculitis, ANCAs are directed against proteinase 3 (PR3) or myeloperoxidase (MPO). The differences between PR3-ANCA-associated vasculitis (AAV) and MPO-AAV described in the past have been supplemented during the last decade. In this review, we discuss the differences between these two small-vessel vasculitides, focusing especially on possible etiologic and pathophysiologic differences. PR3-AAV is more common in northern parts of the world, whereas MPO-AAV is more common in southern regions of Europe, Asia, and the Pacific, with the exception of New Zealand and Australia. A genetic contribution has been extensively studied, and there is a high prevalence of the HLA-DPB1*04:01 allele in patients with PR3-AAV as opposed to patients with MPO-AAV and/or healthy controls. Histologically, MPO-AAV and PR3-AAV are similar but show qualitative differences when analyzed carefully. Clinically, both serotypes are difficult to distinguish, but quantitative differences are present. More organs are affected in PR3-AAV, whereas renal limited vasculitis occurs more often in patients with MPO-AAV. For future clinical trials, we advocate classifying patients by ANCA serotype as opposed to the traditional disease type classification.

26 March 2015 in Autoimmunity
Verified
Journal Article
Closed access
PDF file
Tsuyoshi ShiraiTsuyoshi Shirai
Tsuyoshi Shirai
Marc HilhorstMarc Hilhorst
Marc Hilhorst
DHDavid G. Harrison
David G. Harrison
JGJörg J. Goronzy
Jörg J. Goronzy
Cornelia WeyandCornelia Weyand
Cornelia Weyand
The spectrum of vascular inflammatory disease ranges from atherosclerosis and hypertension, widespread conditions affecting large proportions of the population, to the vasculitides, rare syndromes leading to fast and irreversible organ failure. Atherosclerosis progresses over decades, inevitably proceeding through multiple phases of disease and causes its major complications when the vessel wall lesion ruptures, giving rise to lumen-occlusive atherothrombosis. Vasculitides of medium and large arteries progress rapidly, causing tissue ischemia through lumen-occlusive intimal hyperplasia. In both disease entities, macrophages play a decisive role in pathogenesis, but function in the context of other immune cells that direct their differentiation and their functional commitments. In atherosclerosis, macrophages are involved in the removal of lipids and tissue debris and make a critical contribution to tissue damage and wall remodeling. In several of the vasculitides, macrophages contribute to granuloma formation, a microstructural platform optimizing macrophage–T-cell interactions, antigen containment and inflammatory amplification. By virtue of their versatility and plasticity, macrophages are able to promote a series of pathogenic functions, ranging from the release of cytokines and enzymes, the production of reactive oxygen species, presentation of antigen and secretion of tissue remodeling factors. However, as short-lived cells that lack memory, macrophages are also amendable to reprogramming, making them promising targets for anti-inflammatory interventions.

1 August 2015 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
Marc HilhorstMarc Hilhorst
Marc Hilhorst
PPPieter van Paassen
Pieter van Paassen
HRHenk van Rie
Henk van Rie
NBNele Bijnens
Nele Bijnens
PHPetra Heerings-Rewinkel
Petra Heerings-Rewinkel
FRFor The Limburg Renal Registry
For The Limburg Renal Registry
Anti-neutrophil cytoplasmic antibodies (ANCA) are found in pauci-immune necrotizing crescentic glomerulonephritis. In the past, the role of complement in ANCA-associated vasculitis (AAV) was assumed to be minimal. More recently, however, it was found that blocking the complement cascade in a mouse model of AAV reduces glomerular damage. Immune complex deposits have been found in biopsies from AAV patients. In this study, we questioned whether immune complex formation or deposition may result in complement activation in ANCA-associated glomerulonephritis. ANCA-positive patients from the Limburg Renal Registry were included between 1979 and 2011. Renal histology was documented together with immunoglobulin and complement immunofluorescence. In addition, C3d, properdin, C4d and mannose-binding lectin (MBL) were stained. Electron microscopy was performed. Circulating immune complexes were determined in a subset of patients, as well as C3 allotypes. C3c was found in 78 of 187 renal biopsies (41.7%) divided over 32.3% of proteinase-3 (PR3)-AAV patients and 52.3% of myeloperoxidase (MPO)-AAV patients (P = 0.006), whereas C3d was found positive in 51.1% of PR3-AAV patients and 70.4% of MPO-AAV patients (P = 0.105). C4d was found positive in 70.8%, properdin in 38.7% and MBL in 30.4% of patients. Whereas C4d and MBL positivity was similar between the AGN groups, properdin was more common in biopsies classified as crescentic compared with biopsies classified as focal or mixed. Renal biopsies positive for C3d and/or properdin showed more cellular crescents and less normal glomeruli compared with biopsies negative for C3d and/or properdin (P < 0.05). In 3 out of 43 renal biopsies analysed by electron microscopy, small electron dense deposits were found. In 14 of 46 patients analysed, circulating immune complexes were detectable. No association between histological findings and C3 allotypes was found. In the majority of AAV patients, no immune complex deposits were found in their renal biopsies. C3d, C4d and C5b-9 staining, however, was found to be positive in a majority of analysed renal biopsies. Importantly, C3d and properdin staining was associated with cellular crescents. We hypothesize that local immune complexes are quickly degraded in AAV and therefore not visible by electron microscopy. Our findings are compatible with the hypothesis that complement activation in AAV occurs predominantly via alternative pathway activation.

6 December 2012 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
PDF file
Marc HilhorstMarc Hilhorst
Marc Hilhorst
BWBenjamin Wilde
Benjamin Wilde
PPPieter van Paassen
Pieter van Paassen
Bjorn WinkensBjorn Winkens
Bjorn Winkens
PVPeter van Breda Vriesman
Peter van Breda Vriesman
FRFor The Limburg Renal Registry
For The Limburg Renal Registry
Background Anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis has a poor prognosis. In the current study, we assessed whether prognosis in these patients improved over the last three decades. Methods In a large inception cohort, all consecutive patients with ANCA-associated glomerulonephritis were included between January 1979 and December 2009. Inclusion criteria were the presence of ANCA and the availability of a kidney biopsy. To assess renal and patient survival, patients were divided in three groups through time: 1979–89, 1990–2000 and 2001–09. Results A total of 181 patients were included. One-, 5- and 10-year survival was 77, 66 and 49%, respectively. Survival within the time groups was significantly different, yielding a hazard ratio for death of 2.9 for 1990–2000 and 3.9 for 1979–89 compared with 2001–09 (P < 0.001). Serum creatinine and active lesions as found in the kidney biopsy significantly decreased through the three decades. Conclusions Both patient and renal survival in patients with ANCA-associated renal vasculitis have improved over the last three decades. We postulate that both earlier diagnosis and better therapeutic management of patients are responsible for this effect.

1 August 2013 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
BWB Wilde
B Wilde
MTM Thewissen
M Thewissen
JDJ Damoiseaux
J Damoiseaux
SKS Knippenberg
S Knippenberg
Marc HilhorstMarc Hilhorst
Marc Hilhorst
JTJ W Cohen Tervaert
J W Cohen Tervaert
Objectives B cells have immunoregulatory function acting as antigen-presenting cells. A separate subset of interleukin (IL)-10 producing B cells (Breg) regulating T cell mediated immunity has been identified. In the present study, we investigated the role of Breg in antineutrophil cytoplasmic antibodies-associated vasculitis (AAV). Methods 17 healthy controls (HCs) and 41 patients with AAV were enrolled. 30 patients with AAV were in remission. Furthermore, 11 patients with AAV with active disease were studied. Breg were defined as IL-10+CD19+ B cells upon culture with cytosine-phosphate-guanosine oligodeoxynucleotide (CpG ODN) 2006. Next to Breg, CD4+CD127lowCD25hiCD39neg/CD39+ regulatory T-cells (Treg), interferon (IFN)γ+, IL-4+ and Il-17A+T helper cell subsets were determined via flow cytometry. Results Patients with active or quiescent disease showed a diminished fraction of Breg as compared with HCs. The frequency of IFNγ+ T helper cells was negatively associated with Breg in untreated AAV in remission but not in active vasculitis or in HCs. Interestingly, the total Treg population and the CD39+ Treg subpopulation correlated positively with Breg in inactive patients with AAV. Conclusions IL-10 producing B cells are diminished in AAV. Furthermore, Breg might regulate Th1 cells and are associated with Treg in quiescent AAV. Suppression of Th1 cells by Breg may be insufficient in active AAV.